RT Journal Article SR Electronic T1 An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population JF Clinical Oncology and Cancer Research JO Cancer Biol Med FD China Anti-Cancer Association SP 394 OP 400 DO 10.1007/s11805-009-0394-2 VO 6 IS 6 A1 Yang Shen A1 Zhixiang Shen A1 Bin Jiang A1 Jian Hou A1 Rong Zhan A1 Lugui Qiu A1 Daobin Zhou A1 Jie Jin A1 Juan Li A1 Fanyi Meng A1 Ping Zou A1 Ting Liu A1 Jianyong Li A1 Chun Wang A1 Depei Wu A1 Jun Ma YR 2009 UL http://www.cancerbiomed.org/content/6/6/394.abstract AB OBJECTIVE Though doxorubicin is highly active in the treatment of multiple myeloma, its toxicity profile limits its therapeutic index. We performed this study to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD, Caelyx®), vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma (MM) patients in a Chinese population.METHODS This was an open-label, single-arm study in which newly diagnosed patients with MM received PLD 40 mg/m2 intravenously on Day 1, vincristine 1.4 mg/m2 intravenously (maximum 2 mg) on Day 1, and 40 mg of dexamethasone (intravenously or orally) from Day 1 to Day 4. Treatment was repeated every 28 days for at least 4 cycles.RESULTS In the intent-to-treat (ITT) analysis, the overall response rate was 68.29%, and the complete remission rate was 10.98%. The incidence of all adverse events was 46.34%. The most common non-hematologic toxicities were palmar-plantar erythrodysesthesia (13.4%) and stomatitis (6.1%).CONCLUSION PLD, vincristine, and a reduced-dose dexamethasone combination (DVd) is an effective and safe regimen in newly diagnosed MM patients in a Chinese population.